Identification, Design and Biological Evaluation of Bisaryl Quinolones Targeting Plasmodium falciparum Type II NADH:Quinone Oxidoreductase (PfNDH2)
Open Access
- 24 February 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (5), 1831-1843
- https://doi.org/10.1021/jm201179h
Abstract
A program was undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase (PfNDH2), a dehydrogenase of the mitochondrial electron transport chain of the malaria parasite Plasmodium falciparum. PfNDH2 has only one known inhibitor, hydroxy-2-dodecyl-4-(1H)-quinolone (HDQ), and this was used along with a range of chemoinformatics methods in the rational selection of 17 000 compounds for high-throughput screening. Twelve distinct chemotypes were identified and briefly examined leading to the selection of the quinolone core as the key target for structure–activity relationship (SAR) development. Extensive structural exploration led to the selection of 2-bisaryl 3-methyl quinolones as a series for further biological evaluation. The lead compound within this series 7-chloro-3-methyl-2-(4-(4-(trifluoromethoxy)benzyl)phenyl)quinolin-4(1H)-one (CK-2-68) has antimalarial activity against the 3D7 strain of P. falciparum of 36 nM, is selective for PfNDH2 over other respiratory enzymes (inhibitory IC50 against PfNDH2 of 16 nM), and demonstrates low cytotoxicity and high metabolic stability in the presence of human liver microsomes. This lead compound and its phosphate pro-drug have potent in vivo antimalarial activity after oral administration, consistent with the target product profile of a drug for the treatment of uncomplicated malaria. Other quinolones presented (e.g., 6d, 6f, 14e) have the capacity to inhibit both PfNDH2 and P. falciparum cytochrome bc1, and studies to determine the potential advantage of this dual-targeting effect are in progress.Keywords
This publication has 32 references indexed in Scilit:
- A Research Agenda for Malaria Eradication: DrugsPLoS Medicine, 2011
- Synthesis and Preclinical Evaluations of 2-(2-Fluorophenyl)-6,7-methylenedioxyquinolin-4-one Monosodium Phosphate (CHM-1−P-Na) as a Potent Antitumor AgentJournal of Medicinal Chemistry, 2010
- Type II NADH Dehydrogenase Inhibitor 1-Hydroxy-2-Dodecyl- 4(1H)Quinolone Leads to Collapse of Mitochondrial Inner- Membrane Potential and ATP Depletion inToxoplasma gondiiEukaryotic Cell, 2009
- Semisynthesis and Antiplasmodial Activity of the Quinoline Alkaloid Aurachin EJournal of Natural Products, 2008
- The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyleTrends in Parasitology, 2007
- Similarity-based virtual screening using 2D fingerprintsDrug Discovery Today, 2006
- Functional Characterization and Target Validation of Alternative Complex I of Plasmodium falciparum MitochondriaAntimicrobial Agents and Chemotherapy, 2006
- PowerMV: A Software Environment for Molecular Viewing, Descriptor Generation, Data Analysis and Hit EvaluationJournal of Chemical Information and Modeling, 2005
- XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and MonkeysJournal of Pharmacology and Experimental Therapeutics, 2004
- Human Malaria Parasites in Continuous CultureScience, 1976